These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20146063)

  • 21. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
    Noguchi M; Moriya F; Suekane S; Matsuoka K; Arai G; Matsueda S; Sasada T; Yamada A; Itoh K
    Prostate; 2012 Jun; 72(8):834-45. PubMed ID: 21932426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.
    Qi WX; Shen Z; Yao Y
    J Cancer Res Clin Oncol; 2011 Dec; 137(12):1785-90. PubMed ID: 21915752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
    Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
    Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
    Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.
    Matsumoto K; Tanaka N; Hayakawa N; Ezaki T; Suzuki K; Maeda T; Ninomiya A; Nakamura S
    Med Oncol; 2013 Dec; 30(4):717. PubMed ID: 24005812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
    Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
    Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Yoneyama T; Hashimoto Y; Kamimura N
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):397-401. PubMed ID: 22890389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Michaelson MD; Oudard S; Ou YC; Sengeløv L; Saad F; Houede N; Ostler P; Stenzl A; Daugaard G; Jones R; Laestadius F; Ullèn A; Bahl A; Castellano D; Gschwend J; Maurina T; Chow Maneval E; Wang SL; Lechuga MJ; Paolini J; Chen I
    J Clin Oncol; 2014 Jan; 32(2):76-82. PubMed ID: 24323035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer.
    Hoshi S; Yamaguchi O; Fujioka T; Arai Y; Tomita Y; Habuchi T; Ohyama C; Suzuki T; Orikasa S;
    Int J Clin Oncol; 2006 Aug; 11(4):303-8. PubMed ID: 16937304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
    Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
    J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
    Smaletz O; Galsky M; Scher HI; DeLaCruz A; Slovin SF; Morris MJ; Solit DB; Davar U; Schwartz L; Kelly WK
    Ann Oncol; 2003 Oct; 14(10):1518-24. PubMed ID: 14504052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.
    Hirano D; Nagane Y; Satoh K; Mochida J; Sugimoto S; Ichinose T; Takahashi S; Maebayashi T; Saitoh T
    Int Urol Nephrol; 2010 Mar; 42(1):81-8. PubMed ID: 19449118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : report of a case].
    Kageyama S; Iwaki H; Masuda Y; Yoshida T; Narita M; Okada Y
    Hinyokika Kiyo; 2011 Apr; 57(4):203-7. PubMed ID: 21646852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.
    Uemura H; Fujimoto K; Mine T; Uejima S; de Velasco MA; Hirao Y; Komatsu N; Yamada A; Itoh K
    Cancer Sci; 2010 Mar; 101(3):601-8. PubMed ID: 20128819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Bianco V; Ponchietti R; Barbanti G; Francini E
    Clin Genitourin Cancer; 2015 Oct; 13(5):441-6. PubMed ID: 25920994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.